Tue 08/02/2022 16:33 PM
Oaktree Capital has been buying U.S. Renal Care’s L+500 bps term loan due 2026 and has accumulated a significant position, according to sources.
Market participants are evaluating the possibility of certain lenders to the dialysis provider proposing and executing a transaction that involves funding new money to extend the company’s runway while rolling up their debt holdings that would prime other lenders, known in recent years as creditor-on-creditor violence, the sources...
This article is an example of the content you may receive if you subscribe to a product of Reorg Research, Inc. or one of its affiliates (collectively, “Reorg”). The information contained herein should not be construed as legal, investment, accounting or other professional services advice on any subject. Reorg, its affiliates, officers, directors, partners and employees expressly disclaim all liability in respect to actions taken or not taken based on any or all the contents of this publication. Copyright © 2024 Reorg Research, Inc. All rights reserved.